Zimmer Biomet Holdings, Inc. (ZBH) Financials
Key financial figures for Zimmer Biomet Holdings, Inc. (Q3 2026).
Zimmer Biomet Q3 2026 net sales rose 3.1% to $2.063B (3.7% constant currency) and full-year adjusted EPS guidance was raised to $8.50-$8.60 from $8.47-$8.59, while Knees sales fell 3.1%. Net sales were $2,062.9M, up 3.1% reported and 3.7% on a constant currency basis versus $2,001.4M a year earlier; United States grew 3.6%, International 2.4% reported (3.9% constant currency). Hips grew 6.0% reported (7.0% constant currency), S.E.T. 6.8% (7.1%), and Technology & Data, Bone Cement and Surgical 11.9% (13.0%); Knees declined 3.1% reported (2.6% constant currency) to $767.5M, versus +0.6% for the nine months. On the outlook: Full-year 2026 guidance updated: reported revenue change 4.4%-4.9% (previously 3.9%-4.9%); constant currency revenue change 4.1%-4.6% (previously 3.4%-4.4%); organic constant currency revenue change 3.0%-3.5% (previously 2.25%-3.25%); foreign currency impact +0.25% (previously +0.5%); adjusted diluted EPS $8.50-$8.60 (previously $8.47-$8.59). Figures are for Q3 2026, as Zimmer Biomet Holdings, Inc. reported them.
- Revenue
- $2.1B
- Net Income
- $192M
- EPS
- $1.01
- Total Assets
- $23.5B
- Operating Cash Flow
- $560M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $2.1B | $192M | $1.00 | 14.91% | $373M |
| Q2 FY2026 | $2.2B | $198M | $1.03 | 14.98% | $331M |
| Q1 FY2026 | $2.1B | $238M | $1.22 | 17.88% | $284M |
| Q4 FY2025 | $2.2B | $140M | $0.70 | 12.83% | |
| Q3 FY2025 | $2.0B | $231M | $1.16 | 17.55% |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $8.2B | $705M | $3.55 | 16.55% | $1.5B |
| FY2024 | $7.7B | $904M | $4.43 | 16.74% | $1.1B |
| FY2023 | $7.4B | $1.0B | $4.88 | 17.28% | $1.2B |
Frequently asked questions
What was Zimmer Biomet Holdings, Inc.'s revenue last quarter?
Zimmer Biomet Holdings, Inc. reported revenue of $2.06 billion for Q3 FY2026, up 3.1% from the same period a year earlier.
Is Zimmer Biomet Holdings, Inc. profitable?
Yes. Zimmer Biomet Holdings, Inc. reported net income of $191.6 million for Q3 FY2026, a net margin of 9.29% on revenue.
How has Zimmer Biomet Holdings, Inc.'s margin trended?
Operating margin was 14.91% in Q3 FY2026, compared with 17.55% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Zimmer Biomet Holdings, Inc. generate?
Zimmer Biomet Holdings, Inc. generated free cash flow of $372.5 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Zimmer Biomet Holdings, Inc. on SentiSense, with up to forty quarters and twenty fiscal years of history.